GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (FRA:MWG0) » Definitions » Cyclically Adjusted PB Ratio

InMed Pharmaceuticals (FRA:MWG0) Cyclically Adjusted PB Ratio : 0.01 (As of Jun. 21, 2024)


View and export this data going back to 2004. Start your Free Trial

What is InMed Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-06-21), InMed Pharmaceuticals's current share price is €0.2255. InMed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €30.20. InMed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.01.

The historical rank and industry rank for InMed Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:MWG0' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.04   Max: 1.06
Current: 0.01

During the past years, InMed Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 1.06. The lowest was 0.01. And the median was 0.04.

FRA:MWG0's Cyclically Adjusted PB Ratio is ranked better than
99.85% of 658 companies
in the Biotechnology industry
Industry Median: 1.67 vs FRA:MWG0: 0.01

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

InMed Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was €1.610. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €30.20 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


InMed Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for InMed Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Cyclically Adjusted PB Ratio Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 8.95 2.74 0.35 0.03

InMed Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.03 0.02 0.01 0.01

Competitive Comparison of InMed Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, InMed Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



InMed Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

InMed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.2255/30.2
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, InMed Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.61/126.2576*126.2576
=1.610

Current CPI (Mar. 2024) = 126.2576.

InMed Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201406 22.601 99.473 28.687
201409 19.758 99.394 25.098
201412 14.692 98.367 18.858
201503 16.751 99.789 21.194
201506 16.227 100.500 20.386
201509 11.514 100.421 14.476
201512 9.026 99.947 11.402
201603 6.099 101.054 7.620
201606 8.826 102.002 10.925
201609 9.487 101.765 11.770
201612 12.661 101.449 15.757
201703 20.923 102.634 25.739
201706 35.229 103.029 43.172
201709 31.290 103.345 38.227
201712 59.378 103.345 72.543
201803 49.838 105.004 59.926
201806 85.253 105.557 101.972
201809 82.359 105.636 98.437
201812 75.054 105.399 89.907
201903 68.881 106.979 81.294
201906 58.833 107.690 68.977
201909 49.236 107.611 57.767
201912 39.855 107.769 46.692
202003 29.450 107.927 34.452
202006 24.996 108.401 29.113
202009 18.268 108.164 21.324
202012 22.283 108.559 25.916
202103 27.165 110.298 31.096
202106 19.014 111.720 21.488
202109 31.323 112.905 35.027
202112 22.172 113.774 24.605
202203 17.301 117.646 18.567
202206 13.200 120.806 13.796
202209 12.234 120.648 12.803
202212 8.511 120.964 8.883
202303 3.476 122.702 3.577
202306 3.353 124.203 3.408
202309 2.697 125.230 2.719
202312 2.066 125.072 2.086
202403 1.610 126.258 1.610

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


InMed Pharmaceuticals  (FRA:MWG0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


InMed Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals (FRA:MWG0) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals (FRA:MWG0) Headlines

No Headlines